Published on 21/12/2025
Step-by-Step Case Study of BE Submission for a Generic Antihypertensive Drug
Background and Objective of the BE Submission
This case study explores the successful submission and approval of a bioequivalence (BE) study for a generic version of amlodipine besylate, a widely used antihypertensive agent. The primary objective was to establish therapeutic equivalence to the reference listed drug (RLD) through a well-designed in vivo BE study and to secure regulatory approval through the Abbreviated New Drug Application (ANDA) process.
Amlodipine, a dihydropyridine calcium channel blocker, is classified as a BCS Class I drug (high solubility, high permeability), yet due to excipient differences and target market regulatory requirements, a full in vivo BE study was conducted instead of relying on a biowaiver.
Regulatory Pathway and Initial Planning
The sponsor targeted the U.S. FDA and EMA for submission. Strategic planning began with evaluating the following:
- Patent status and market exclusivity timelines for the RLD
- Suitability of the formulation for BCS-based waiver (ultimately decided against due to minor excipient variation)
- Design of an in vivo, two-period, two-sequence crossover study in healthy volunteers
The reference product was Norvasc® 5 mg tablet. The target market included the U.S., EU, and WHO-PQP-regulated countries. Therefore,
Study Design Overview
The BE study was conducted at a WHO-accredited CRO site. Key parameters:
- Design: Open-label, randomized, two-period crossover
- Subjects: 32 healthy male volunteers (aged 18–45 years)
- Dose: Single oral dose of 5 mg (test and reference)
- Washout period: 14 days
- Sample collection: Pre-dose and up to 72 hours post-dose
The protocol and informed consent documents were approved by an Ethics Committee, and the study was registered on CTRI prior to initiation.
Pharmacokinetic Sampling and Analytical Validation
Plasma concentrations of amlodipine were measured using a validated LC-MS/MS method. Method validation followed FDA guidance for bioanalytical method validation with the following metrics:
- LOD: 0.2 ng/mL
- LOQ: 0.5 ng/mL
- Calibration range: 0.5 to 20 ng/mL
- Intra-batch precision: CV% < 10%
- Accuracy: 95%–105%
Stability studies confirmed sample integrity for 30 days at -20°C.
Key Pharmacokinetic Parameters and Results
| Parameter | Test | Reference | 90% CI |
|---|---|---|---|
| Cmax (ng/mL) | 7.42 | 7.36 | 98.3% – 101.7% |
| AUC0–t (ng·h/mL) | 140.8 | 138.5 | 97.6% – 103.4% |
| AUC0–∞ (ng·h/mL) | 155.2 | 152.8 | 98.1% – 102.6% |
| Tmax (h) | 5.8 | 5.6 | — |
All PK parameters fell within the regulatory acceptance range of 80.00%–125.00% for log-transformed Cmax and AUC values.
Statistical Analysis Approach
Data was analyzed using the following method:
- ANOVA model with sequence, period, treatment, and subject (nested within sequence)
- 90% confidence intervals calculated for log-transformed Cmax, AUC0–t, and AUC0–∞
- No significant sequence effect (p > 0.05)
- Residual error within acceptable range (CV% < 20%)
Documentation and eCTD Submission
The BE submission was structured in CTD format with emphasis on:
- Module 1: Regional information and cover letter
- Module 2: Quality overall summary and clinical overview
- Module 3: Detailed description of formulation development
- Module 5: Complete BE study report, bioanalytical validation, and subject safety data
The final package was submitted via the Electronic Common Technical Document (eCTD) gateway.
Outcome and Approval Timeline
Key milestones:
- Study completion to dossier compilation: 2.5 months
- FDA review time: 8 months (priority review granted)
- Outcome: Approval granted with no major queries or deficiencies
Following FDA approval, the same study report was accepted by the EMA under the Mutual Recognition Procedure (MRP), reducing duplication of effort and accelerating EU entry.
Lessons Learned and Best Practices
- Engage regulatory consultants early to define submission strategy
- Ensure real-time method validation and equipment calibration logs are audit-ready
- Document even minor formulation changes to avoid waiver rejection
- Plan sufficient washout periods to prevent carryover in crossover designs
- Use real-world comparator product batches with valid expiry and procurement records
Conclusion: A Model BE Submission for Generic Success
This case study illustrates a successful, streamlined BE submission for a generic antihypertensive drug. By aligning study design with global regulatory expectations and ensuring accurate, reproducible pharmacokinetic data, the sponsor achieved approval in multiple markets with a single BE trial. The outcome serves as a replicable template for future generic submissions involving similar therapeutic classes.